Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Nutr ; 32(3): 444-51, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23068014

RESUMEN

BACKGROUND & AIMS: Changes in the microbiota composition are able to affect nutrient absorption and energy metabolism, but there are few human studies. The aims were to analyze fecal constituents quantitatively and compare them with liver dysfunction in hepatic cancer patients and to evaluate the relationships among intestinal microbiota, fecal organic acids and plasma lipid composition. METHODS: Fecal samples collected from 46 hepatic cancer patients (with liver cirrhosis, chronic hepatitis or liver fibrosis and normal liver) were evaluated for fecal constituents. Blood organic acid, lipid and fatty acid concentrations were analyzed. RESULTS: Fecal microbiota and organic acids showed no significant differences among different liver dysfunction patients. In normal liver patients, fecal Candida was positively correlated with plasma phospholipid while Bifidobacterium was negatively correlated with plasma eicosapentaenoic acid and eicosapentaenoic acid/arachidonic acid ratio (all p < 0.05). In cirrhotic liver patients, positive correlations were noted for Lactobacillus and docosahexaenoic acid and Candida and eicosapentaenoic acid or eicosapentaenoic acid/arachidonic acid ratio (all p < 0.01). It was suggested that intestinal biota affected serum fatty acid metabolism and were modified by liver disorders. CONCLUSIONS: Intestinal microbiota and organic acid concentrations in hepatic cancer patients had positive and/or negative correlations with serum lipid levels.


Asunto(s)
Heces/microbiología , Intestinos/microbiología , Lípidos/sangre , Cirrosis Hepática/sangre , Neoplasias Hepáticas/sangre , Microbiota , Ácidos/sangre , Anciano , Ácido Araquidónico/sangre , Bifidobacterium/aislamiento & purificación , Candida/aislamiento & purificación , Ácidos Docosahexaenoicos/sangre , Ácido Eicosapentaenoico/sangre , Femenino , Humanos , Lactobacillus/aislamiento & purificación , Metabolismo de los Lípidos , Cirrosis Hepática/fisiopatología , Neoplasias Hepáticas/fisiopatología , Masculino , Persona de Mediana Edad , Fosfolípidos/sangre
2.
JPEN J Parenter Enteral Nutr ; 35(3): 317-28, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21527594

RESUMEN

BACKGROUND: The aim of this study was to assess the effect of preoperative and postoperative synbiotic treatment in hepatectomy patients with or without liver cirrhosis. METHODS: Sixty-one patients with hepatic cancer were assigned randomly to receive either oral synbiotics that consisted of Bifidobacterium, Lactobacillus, and galactooligosaccharides or no synbiotics (control) preoperatively for 14 days and postoperatively for 11 days. Infectious complications, intestinal mucosal integrity as measured by serum diamine oxidase (DAO) activity, and fecal flora and organic acid concentrations were compared between synbiotic treatment (n = 32) and control (n = 29) groups. RESULTS: Fecal flora culture and organic acid concentrations were changed after hepatectomy in both groups. The postsurgery decrease in DAO activity was less profound in the synbiotic-treated group (P < .01) and was correlated negatively with serum interleukin 6 and C-reactive protein concentrations (P < .001). Infectious complications occurred in 5 (17.2%) patients in the control group and no patients in the synbiotic-treated group (P < .05). CONCLUSION: Perioperative synbiotic treatment attenuated the decrease in intestinal integrity and reduced the rate of infectious complications in patients with or without liver cirrhosis who underwent hepatic surgery.


Asunto(s)
Heces/microbiología , Infecciones/epidemiología , Mucosa Intestinal , Hígado/cirugía , Complicaciones Posoperatorias/terapia , Simbióticos , Ácidos/análisis , Anciano , Amina Oxidasa (conteniendo Cobre)/sangre , Bifidobacterium , Proteína C-Reactiva/metabolismo , Heces/química , Femenino , Humanos , Incidencia , Infecciones/metabolismo , Interleucina-6/sangre , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Lactobacillus , Cirrosis Hepática/cirugía , Neoplasias Hepáticas/cirugía , Masculino , Persona de Mediana Edad , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Atención Perioperativa/métodos , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA